Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide Inhalation for Severe COVID-19
NCT04290871Phase 2Withdrawn
- Sponsor
- Xijing Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
01
Overview
A Phase 2 trial of nitric oxide in coronavirus disease 2019 (COVID-19), sponsored by Xijing Hospital. Planned start Jan 2023; status: withdrawn.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04290871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290871.